Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism.

[1]  Manasa Murthy,et al.  Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study , 2015, Thrombosis.

[2]  M. Prins,et al.  Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program , 2015, Current medical research and opinion.

[3]  M. Prins,et al.  Treatment of Pulmonary Embolism With Rivaroxaban: Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the EINSTEIN PE Study , 2015, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[4]  S. Mody,et al.  Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States. , 2015, Clinical therapeutics.

[5]  S. Mody,et al.  Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program , 2014, Journal of medical economics.

[6]  G. Lip,et al.  New Oral Anticoagulants in Elderly Adults: Evidence from a Meta‐Analysis of Randomized Trials , 2014, Journal of the American Geriatrics Society.

[7]  C. Coleman,et al.  Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants , 2014, Current medical research and opinion.

[8]  M. Prins,et al.  Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism , 2014, Current medical research and opinion.

[9]  S. Mody,et al.  Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism , 2014, Journal of medical economics.

[10]  P. Wells,et al.  Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. , 2013, Thrombosis research.

[11]  G. Raskob,et al.  Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies , 2013, Thrombosis Journal.

[12]  E. Kuipers,et al.  New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. , 2013, Gastroenterology.

[13]  H. Bloomfield,et al.  Updated guidelines on outpatient anticoagulation. , 2013, American family physician.

[14]  A. Linhart,et al.  Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. , 2013, Experimental and clinical cardiology.

[15]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[16]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[17]  G. Andersen,et al.  In-Hospital Medical Complications, Length of Stay, and Mortality Among Stroke Unit Patients , 2011, Stroke.

[18]  C. Thilo,et al.  Effectiveness of thrombolysis in patients with intermediate-risk pulmonary embolism: Influence on length of hospital stay , 2010, Advances in therapy.

[19]  J. Bernhardt,et al.  Very Early Mobilisation and Complications in the First 3 Months after Stroke: Further Results from Phase II of A Very Early Rehabilitation Trial (AVERT) , 2009, Cerebrovascular Diseases.

[20]  Piotr Pruszczyk,et al.  Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism , 2008 .

[21]  D. Waller.  How VA hospitals became the best. , 2006, Time.

[22]  P D Cleary,et al.  Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. , 2001, Journal of clinical epidemiology.

[23]  W. Kukull,et al.  Medical complications of ischemic stroke and length of hospital stay: experience in Seattle, Washington. , 1999, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.